ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) Meeting Abstract
| Authors: | Sehn, L. H.; Kahl, B. S.; Matasar, M. J.; Lenz, G.; Izutsu, K.; Zhao, W.; Tao, L.; Calvo, R.; Zinzani, P. L. |
| Abstract Title: | ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120307019 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.TPS7572 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS7572 -- Source: Wos |
